On August 19, 2022 (“Closing”), Organicell Regenerative Medicine, Inc. consummated its previously announced $4.0 million capital raise and corporate restructuring transaction. At Closing, Albert Mitrani, Dr. Allen Meglin and Michael Carbonara stepped down as directors of the Company. It is anticipated that additional directors will be appointed to the board, the majority of whom will be “independent” in accordance with the rules and regulations of the SEC and the Nasdaq Stock Market, LLC.